Genomic Health Announces Positive Topline Results of Additional, Large Independent Validation Study of Oncotype DX® Prostate C

    Genomic Health Announces Positive Topline Results of Additional, Large
    Independent Validation Study of Oncotype DX® Prostate Cancer Test with
                         Multiple Clinical Endpoints

Study Achieved Primary Endpoint of Predicting Recurrence after Surgery and
Reconfirmed Original Adverse Pathology Endpoint from Published UCSF Validation

Data Submitted for Presentation at Medical Meeting Later this Year

PR Newswire

REDWOOD CITY, Calif., Aug. 6, 2014

REDWOOD CITY, Calif., Aug. 6, 2014 /PRNewswire/ -- Genomic Health, Inc.
(Nasdaq: GHDX) today announced positive preliminary results from an additional
independent clinical validation study conducted by the Center for Prostate
Disease Research (CPDR) demonstrating that the Oncotype DX^® Genomic Prostate
Score (GPS) predicts multiple clinical endpoints related to disease
aggressiveness in men with low- and intermediate-risk prostate cancer. This
study validated the Oncotype DX prostate cancer test as a predictor of
biochemical recurrence, a rise in prostate-specific antigen (PSA) following
surgery, which is a measure of longer-term outcomes for aggressive disease. It
also reconfirmed the test's ability to predict adverse pathology from the
biopsy, as previously demonstrated in a published validation study performed
by the University of California, San Francisco (UCSF). 

Additional, important endpoints of this landmark prostate cancer study include
the development of metastatic disease and outcomes in African-American
patients.Genomic Health and CPDR have submitted the results from this study
for medical meeting presentation later this year.

"Given the need for more accurate risk stratification of men with newly
diagnosed prostate cancer, our prospectively designed and rigorously conducted
study provides further validation of the earlier studies at Cleveland Clinic
and UCSF showing that the Oncotype DX test is an independent predictor of
clinical outcomes in patients with low- and intermediate-risk disease," said
Shiv Srivastava, Ph.D., co-director of CPDR who led the evaluation of the
Oncotype DX test and its utility as an independent predictor of clinical
outcomes under a Cooperative Research and Development Agreement with the
Uniformed Services University's (USU) CPDR.

The CPDR is a multi-disciplinary prostate cancer research program of the
Department of Surgery, USU, the Department of Defense's federal health
sciences university, and it is a collaboration with The Henry M. Jackson
Foundation for the Advancement of Military Medicine, Inc., a private,
not-for-profit organization authorized by Congress to support medical research
and education at the Uniformed Services University of the Health Sciences.

"In the past year, the growing number of physicians and patients using the
Oncotype DX prostate cancer test demonstrates the value it provides to help
make the most appropriate choice between immediate treatment or active
surveillance," said Phil Febbo, M.D., chief medical officer, Genomic Health.
"Once presented,we believe these new results will further increasephysician
and patient confidence in theOncotype DX prostate cancer test and allow more
men with recently diagnosed prostate cancer to make a better informed
treatment decision based upon the biology of their individual cancer."

More than fifty percent of men diagnosed with prostate cancer have low-risk
disease with less than a three percent chance of developing advanced,
life-threatening disease. However, the large majority currently receive
immediate invasive treatment because conventionalclinical and pathological
evaluations of their needle biopsies do not adequately predict whether
aggressive cancer ispresent in the prostate at time of diagnosis.

Developed and validated in collaboration with Cleveland Clinic and UCSF, the
Oncotype DX prostate cancer test addresses the unique challenges in making
treatment decisions for men with clinically localized prostate cancer, by
identifying patients who can consider active surveillance with greater
confidence and thus avoid unnecessary treatment, as well as those men who have
more aggressive disease and should consider immediate treatment.

About Genomic Health

Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of
genomic-based diagnostic tests that address both the overtreatment and optimal
treatment of early stage cancer, one of the greatest issues in healthcare
today. The company is applying its world-class scientific and commercial
expertise and infrastructure to lead the translation of massive amounts of
genomic datainto clinically-actionable results for treatment planning
throughout the cancer patient's journey, from screening and surveillance,
through diagnosis, treatment selection and monitoring.Genomic Health's lead
product, the Oncotype DX® breast cancer test, has been shown to predict the
likelihood of chemotherapy benefit as well as recurrence in invasive breast
cancer and has been shown to predict the likelihood of recurrence in ductal
carcinoma in situ (DCIS).In addition to this widely adopted test, Genomic
Health provides the Oncotype DX colon cancer test, the first multi-gene
expression test developed for the assessment of risk of recurrence in patients
with stage II and stage III disease, and the Oncotype DX prostate cancer test,
which predicts disease aggressiveness in men with low risk disease. As of
March 31, 2014, more than 19,000 physicians in over 70 countries had ordered
more than 440,000 Oncotype DX tests.The company is based in Redwood City,
California with European headquarters in Geneva, Switzerland. For more
information, please visit, and follow the company on
Twitter: @GenomicHealth. To learn more about OncotypeDX tests, visit:, and

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, including statements
relating to the potential benefits of the company's tests for patients with
prostate cancer; limitations of current treatment options;the company's
expectations regarding reporting study results; the attributes and focus of
the company's product pipeline; the applicability of clinical study results to
actual outcomes; the ability of any potential tests the company may develop to
optimize cancer treatment; and the ability of the company to develop and
commercialize additional tests in the future. Forward-looking statements are
subject to risks and uncertainties that could cause actual results to differ
materially, and reported results should not be considered as an indication of
future performance. These risks and uncertainties include, but are not limited
to: the risks and uncertainties associated with the regulation of the
company's tests; the full results of the clinical study; the applicability of
clinical study results to actual outcomes; our ability to develop and
commercialize new tests and expand into new markets domestically and
internationally; the risk that the company may not obtain or maintain
sufficient levels of reimbursement, domestically or abroad, for its existing
tests and any future tests it may develop; the risks of competition;
unanticipated costs or delays in research and development efforts; the
company's ability to obtain capital when needed and the other risks set forth
in the company's filings with the Securities and Exchange Commission,
including the risks set forth in the company's quarterly report on Form 10-Q
for the quarter ended March 31, 2014. These forward-looking statements speak
only as of the date hereof. Genomic Health disclaims any obligation to update
these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype and Oncotype DX are trademarks or
registered trademarks of Genomic Health, Inc. All other trademarks and service
marks are the property of their respective owners.

SOURCE Genomic Health, Inc.

Contact: Investors: Emily Faucette, Genomic Health, 650-569-2824,; Media: Victoria Steiner, Genomic Health,
Press spacebar to pause and continue. Press esc to stop.